APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Apnimed, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$16.59−1.17 (-6.56%)
Close on Oct 19, 2026
- Market cap
- $536.90M
- P/E (TTM)
- –
- Dividend yield
- –
About Apnimed
Pharmaceutical Preparations, SIC 2834
Apnimed, Inc. is listed on Nasdaq under the ticker APMD, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Apnimed, Inc.
- Headquarters
- Cambridge, MA
- Address
- 39 John F. Kennedy Street, 4th Flr. 02138
- Phone
- (617) 500-8880
- Website
- apnimed.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- APMD
- Exchange
- Nasdaq
- IPO date
- Jul 31, 2026
- Shares outstanding
- 42M, Sep 4, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1745648
- CUSIP
- 03770Y107
- ISIN
- US03770Y1073
- EIN
- 82-1910611
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin Robert Lind | Chief Executive Officer, Director | – |
| Michael B. Kelly | Chief Financial Officer | – |
| Dennis Patrick Molnar | President | 58,014 |
| Paul R. Fonteyne | Director | – |
| William A. Jones Jr | Director | – |
| Paul J. Sekhri | Director | 12,500 |
| Gary Sender | Director | – |
| Lawrence G. Miller | Director | 459,092 |
| Chris Dimitropoulos | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 29, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |